Project Grant HT9425261E184
Award Date 6/1/26
Completion Date 5/31/29
Dollars Obligated $2.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- Federal Grant Award Summary New York University School of Medicine has received a $2.54 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025 through July 31, 2028. The award supports research and development activities focused on advancing a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS) treatment through investigation of the RAGE/DIAPH1 axis. As a premier academic medical...
- This $879,721 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research to evaluate small molecule ferroptosis inhibitors in a Gtp4-associated amyotrophic lateral sclerosis (ALS) model at Columbia University. The research aims to transform healthcare for military service members and the broader public by developing innovative medical solutions to address critical health challenges. The award is effective from...
- The Trustees of Columbia University in New York City will receive $486,000 from the Defense Health Agency through March 2024 to analyze the adaptive and innate immune response in patients with amyotrophic lateral sclerosis (ALS) who have been treated with antisense oligonucleotides. This Project Grant was awarded on April 1, 2021 under the Military Medical Research and Development program (CFDA 12.420). The Defense Health Agency's Military Medical Research and Development program aims to...
- Federal Grant Award Summary New York University School of Medicine received a $1.0 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from June 1, 2026, through May 31, 2029. The award funds research into diffusion magnetic resonance imaging (MRI) biomarkers of axonal degeneration in amyotrophic lateral sclerosis (ALS). This research initiative will advance understanding of neurodegeneration...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,490,000.00 to the University of Southern California (USC) to develop a VAV2 antisense oligonucleotide therapeutic for amyotrophic lateral sclerosis (ALS). The award period runs from March 1, 2025 to February 28, 2027. USC, a leading private research university, will leverage its expertise in advanced biomedical research to pursue this innovative...
- This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop neuronal exosome-based biomarkers for the diagnosis and disease progression of amyotrophic lateral sclerosis (ALS). The total award amount is $1,181,251.00, with a performance period from April 15, 2025 to April 14, 2028. The principal investigator for this grant is the University of California, Los Angeles (UCLA), which has a...
- Federal Project Grant Award Summary The University of Miami's Office of Research Administration - School of Medicine received a $999,999 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on June 1, 2026. The award funds research titled "Schwann Cell-Derived Extracellular Vesicle Platform for ALS Biomarker Discovery in Biofluids" with a completion date of May 31, 2029. This project delivers biomarker discovery research...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Denver Research Institute a $2.31M Project Grant under the Military Medical Research and Development program (CFDA 12.420) beginning July 1, 2025, and concluding June 30, 2029. The award funds the Development and Evaluation of a Care Pathway for Evaluation and Management of the Respiratory Syndromes of Amyotrophic Lateral Sclerosis (CAPRESA), a clinical research initiative to be conducted at the Institute's Denver, Colorado...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Trustees of Columbia University in the City of New York's Health Sciences Division a $1.645 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research on treating HER2 therapy-resistant brain metastasis using antidepressants, conducted at Columbia's Health Sciences Division facility in New York, NY. This project...
- Federal Grant Award Summary Yale University received a $839,991 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period May 1, 2026 through April 30, 2028. The award supports research focused on targeting neuronal calcium sensor-1 as a novel therapeutic approach for amyotrophic lateral sclerosis (ALS). The research will be conducted at Yale's facilities in New Haven, Connecticut. This award represents a...